DWJ1691

DWJ1691 is a long-acting injectable drug candidate being developed by Daewoong Pharmaceutical for the treatment of obesity. The formulation is designed for once-monthly administration, utilizing Daewoong's proprietary "Smart Depot" technology to achieve sustained release of the active ingredient. This technology employs biodegradable polymers to encapsulate the drug, providing a controlled release profile that aims to improve patient adherence and convenience compared to more frequent dosing schedules. DWJ1691 functions as a Glucagon-like peptide 1 (GLP-1) receptor agonist, mimicking the effects of the natural GLP-1 hormone to regulate appetite, increase satiety, and manage glucose metabolism, thereby promoting weight loss.